Biogen and Sage Therapeutics in Global Collaboration
- Posted by ISPE Boston
- On December 3, 2020
Biogen and Sage Therapeutics have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders. “We are excited about the potential to bring together Biogen’s leading capabilities in neuroscience with Sage’s […]
Read More